Glenmark Pharma FY26 PAT Rises 30.1% to ₹13,620 Million; Q4 EBITDA Jumps to ₹9.4b
Glenmark Pharmaceuticals reported a 30.1% YoY rise in FY26 PAT to ₹13,620 million, with consolidated revenue growing 27.5% to ₹169,825 million and EBITDA margin at 26.9%. In Q4 FY26, net profit surged to ₹3b from ₹465m YoY, while EBITDA expanded to ₹9.4b with margin improving to 25% from 17.23%. The year was marked by a landmark AbbVie licensing deal for ISB 2001 worth up to $1.925 billion and strong operational momentum across India, North America, and Emerging Markets.
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals Limited reported a 30.1% year-on-year increase in Profit After Tax (PAT) to ₹13,620 million for the financial year ended March 31, 2026. Consolidated revenue for FY26 grew 27.5% to ₹169,825 million, driven by robust growth across key geographies and strategic progress in its innovation portfolio. The company's EBITDA for the year stood at ₹45,724 million, reflecting an EBITDA margin of 26.9%. The performance was bolstered by a landmark licensing deal with AbbVie for ISB 2001 and strong momentum in its India and North America businesses.
Q4 FY26 Performance
For the fourth quarter of FY26, consolidated revenue grew to ₹37.6b versus ₹32.6b in the same period last year. EBITDA for the quarter rose sharply to ₹9.4b compared to ₹5.6b year-on-year, with EBITDA margin expanding to 25% from 17.23%. Net profit for the quarter came in at ₹3b versus ₹465m in the corresponding quarter of the previous year. The North America business recorded revenue of ₹9,248 million, a growth of 29.4% YoY, bolstered by deferred out-licensing income recognition for ISB 2001. Net of this income, the core business in the region grew 7.8%. The India business grew 8.2% YoY to ₹10,201 million in Q4, while Europe and Emerging Markets grew 21.4% and 13.7% respectively.
The following table summarises the key Q4 FY26 financial metrics on a year-on-year basis:
| Metric: | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Consolidated Revenue: | ₹37.6b | ₹32.6b |
| EBITDA: | ₹9.4b | ₹5.6b |
| EBITDA Margin: | 25% | 17.23% |
| Net Profit: | ₹3b | ₹465m |
Full-Year FY26 Financial Summary
The annual financial performance is captured in the table below:
| Metric: | FY26 | FY25 | Growth (%) |
|---|---|---|---|
| Consolidated Revenue: | ₹169,825 million | ₹133,217 million | 27.5% |
| EBITDA: | ₹45,724 million | Not Provided | - |
| PAT: | ₹13,620 million | Not Provided | - |
| EBITDA Margin: | 26.9% | Not Provided | - |
Operational Highlights
Glenmark's India business delivered strong outperformance, growing at 1.5x the IPM growth. The company ranked as the 2nd fastest-growing company among the top 15 in FY26 as per IQVIA. Key product launches included TEVIMBRA® and BRUKINSA® in Oncology, Nebzmart GFB Smartules® in Respiratory, and GLIPIQ® for Diabetes. RYALTRIS® recorded over 50% growth in secondary sales across commercial markets, with end-to-end commercialization initiated in the USA. The Monroe manufacturing facility received a U.S. FDA EIR with VAI classification, enabling the restart of commercial manufacturing.
Strategic Developments
Ichnos Glenmark Innovation (IGI) secured a landmark licensing deal with AbbVie for ISB 2001, involving an upfront payment of $700 million and a potential total deal value of $1.925 billion. Glenmark will lead commercialization across Emerging Markets. The company also accelerated its Oncology business expansion through in-licensing agreements for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma. Additionally, Glenmark strengthened its generic respiratory portfolio in the US with the first generic approval of Flovent® HFA 44 mcg.
Dividend Recommendation
The Board of Directors recommended a final dividend of 250%, or ₹2.5 per equity share of face value Re. 1 each, for the financial year 2025-26. The payment is subject to the approval of shareholders at the ensuing Annual General Meeting.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.57% | +1.06% | -3.53% | +6.93% | +29.36% | +240.37% |
How will Glenmark utilize the $700 million upfront payment from the AbbVie deal to balance debt reduction versus future R&D investments?
What is the projected revenue contribution from the newly launched oncology products, TEVIMBRA® and BRUKINSA®, over the next two fiscal years?
With the Monroe facility receiving FDA approval, what is the timeline for ramping up commercial production and its expected impact on US market supply?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
